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Title 1 Associations of First Trimester Co-use of Tobacco and Cannabis with Prenatal Immune 2 Response and Psychosocial Well-Being 3 
Abstract  4 
Purpose. This study aims to describe the association of first trimester co-use of tobacco and 5 cannabis with maternal immune response and psychosocial well-being, relative to tobacco use only. 6 
Methods. A preliminary midpoint analysis included 138 pregnant women with biologically 7 verified tobacco use, 38 of whom (28%) also tested positive for recent cannabis use. Maternal 8 perceived stress (Perceived Stress Scale), depressive symptoms (Edinburgh Postnatal 9 Depression Scale), and serum immune markers (IL-1β, IL-2, IL-6, IL-8, IL-10, TNFα, CRP, 10 MMP8), were collected, although cytokine data were only available for 122 women.  11 
Results. Participant average age was 29.1 years, approximately half had a high school education or 12 less, and half were unemployed. Compared to tobacco only users, co-users were more likely to be 13 non-White, younger and more economically disadvantaged. In the adjusted linear regression 14 models, TNF-α levels were significantly lower among co-users relative to tobacco only users, after 15 adjusting for age, race/ethnicity, body mass index and tobacco use group (tobacco cigarettes, 16 electronic nicotine delivery devices [ENDS] or both). TNF-α was the only immune marker found to 17 be significant in this analysis. Measured stress levels (M=5.9, SD=3.3; potential range 0-16) and 18 depression scores (M=7.8, SD=5.8; potential range 0-30) were low across all participants and did 19 not differ as a function of co-use. 20 
Conclusion. Preliminary results suggest women co-using during the first trimester exhibit 21 decreased pro-inflammatory immune responsivity on one out of eight markers. Further research is 22 needed to determine the impact of this immune modulation on fetal health outcomes and the 23 unique contribution of cannabis. 24 
Key Words:  marijuana; nicotine; cytokines; pregnancy; perceived stress  25 
26 
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Introduction 27 
  28 Tobacco and cannabis are the two most common addictive substances used during 29 pregnancy, and are often used concurrently. Nearly 90% of cannabis users are also tobacco 30 smokers (Rabin & George, 2015), and there has been a recent rapid and disproportionate increase 31 in daily cannabis use among female cigarette smokers compared to male smokers (Goodwin et al., 32 2018). This is of significant concern due to pregnant women being at increased risk of continued 33 use for the duration of their pregnancy (El Marroun et al., 2008; Ko et al., 2015). United States (US) 34 nation-wide survey data reflect that 20% of pregnant women co-use tobacco and cannabis, 35 (Azofeifa, 2016), with those aged 18-25 years old being more likely to co-use tobacco and cannabis 36 than cannabis alone (Coleman-Cowger, Schauer, & Peters, 2017). Yet, other recent studies using 37 large databases from individual prenatal clinics indicate that the number of pregnant concurrent 38 users of cannabis and tobacco is considerably higher (approaching 50%) (Chabarria et al., 2016; 39 Mark, Desai, & Terplan, 2016).  40 The consequences of tobacco use during pregnancy have been studied extensively. Nicotine, 41 the primary active constituent of tobacco, is a teratogen and classified as a pregnancy class D drug 42 by the US Food and Drug Administration. Tobacco exposure during pregnancy is associated with 43 numerous adverse physical and psychosocial health effects including, but not limited to, 44 spontaneous preterm birth, small for gestational age infant, placenta previa, placenta abruption, 45 impaired fetal lung and brain development and miscarriage (American College of Obstetricians and 46 Gynecologists, 2017; Castles, Adams, Melvin, Kelsch, & Boulton, 1999; Centers for Disease Control 47 and Prevention, 2018; Kharrazi et al., 2004; Warren, Albert, Kraft & Cummins, 2014). Other adverse 48 health effects of prenatal tobacco exposure extend beyond birth and include increased risk for 49 sudden infant death syndrome and numerous respiratory, metabolic, neurobiological and 50 behavioral disorders (e.g. asthma, obesity and attention deficit hyperactivity disorder) (Langely, 51 
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Rice & Thapar, 2005; Maritz & Harding, 2011; Oken, Levitan & Gillman, 2008; Weg, Ward, Scarinci, 52 Read, Evans, 2004; Wickstrom, 2007).  53 Prior work is also suggestive of interactions among prenatal tobacco use, immune 54 dysregulation in the mother, and maternal depression and anxiety (Osborne & Monk, 2013; 55 Coussons-Read, Okun & Nettles, 2007). High levels of maternal depression and anxiety symptoms 56 are associated with shorter gestation, alterations in fetal neurodevelopment (Schetter & Tanner, 57 2012) and lower visuospatial working memory performance in the offspring (Buss, Davis, Hobel & 58 Sandman, 2011).These maternal psychiatric symptoms are also often associated with immune 59 dysregulation in pregnant women, commonly resulting in high circulating serum C-reactive protein 60 (CRP) and proinflammatory cytokines (i.e., interleukin [IL]-6 and tumor necrosis factor [TNF]-α), 61 and lower levels of the anti-inflammatory cytokine, IL-10 (Christian, Franco, Glaser, & Iams, 2009; 62 Coussons-Read, Okun, Schmitt, & Giese, 2005). Further, nicotine directly affects the immune system. 63 In an animal study by Nouri-Shirazi and Guinet (2013), nicotine significantly depressed antibody 64 responses and T-cell proliferation. A study of microglial activation linked nicotine exposure to 65 significantly decreased levels of pro-inflammatory cytokines including interleukin (IL) -6 and TNF- 66 
α (Jia et al., 2016). In pregnancy, first trimester tobacco use has been associated with maternal 67 immune dysregulation. For example, significant anti-inflammatory reductions in cervical IL-10 68 were observed in women using tobacco early in pregnancy compared to nonsmokers whereas 69 proinflammatory cytokines (IL-1α, 1β, 2, 4, 6, 8, TNFα) did not change. (Ashford, O'Brien, McCubbin, 70 Westneat, & Barnett, 2013; Simhan, Caritis, Hillier, & Krohn, 2005). An examination of serum 71 cytokines in the second and third trimesters of pregnancy revealed significantly higher 72 concentrations of IL-6 and IL-1α among smokers compared to non-smokers (Ashford, Barnett, 73 McCubbin, Kehler, Westneat, 2013). Maternal immune dysregulation is of concern because it has 74 been linked to adverse perinatal outcomes including pre-eclampsia (Ashford et al., 2017) and 75 preterm birth (Goldenberg, Culhane, Iams, & Romero, 2008; Simhan and Krohn, 2009).  76 
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Within the past two decades, the perceived risk of cannabis use has decreased (Berg et al., 77 2015; Sinclair, Foushee, Scarinci, & Carroll, 2013) and public acceptance of cannabis use has 78 increased (Pew Research Center, 2018) in the United States. Perhaps unsurprisingly then, the 79 percentage of national survey respondents reporting past-year cannabis use has also increased 80 (United Nations Office on Drugs and Crime, 2017). Cannabis use in the first trimester of pregnancy 81 has been reported as high as 7.4%, with 16% of users reporting daily cannabis use (Ko, Farr, Tong, 82 Creanga, & Callaghan, 2015). Prenatal cannabis use may occur for various reasons including 83 recreation and self-medication (Ko et al., 2015; Park, McPartland, & Glass, 2004; Wang, Dow-84 Edwards, Anderson, Minkoff, & Hurd, 2004). Among women who used cannabis during pregnancy, 85 some endorsed its use as a means to treat nausea and vomiting (Westfall, Janssen, Lucas, & Capler, 86 2006). Although ∆9- tetrahydrocannabinol (THC; the primary active constituent of cannabis) is 87 FDA-approved as a treatment for nausea and vomiting associated with cancer chemotherapy, it has 88 not been evaluated for hyperemesis gravidarum, a pregnancy complication resulting in severe 89 nausea, vomiting and alteration in serum electrolytes. 90 The consequences of cannabis use during pregnancy are less clear compared to those of 91 tobacco. Prior research has shown that THC crosses the placenta, although the levels are reduced 92 compared to maternal concentrations (Grant, Petroff, Isoherranen, Stella, & Burbacher, 2017). 93 Some studies have found adverse outcomes such as increased risk of preterm birth (Burns, Mattick, 94 & Cooke, 2006), decreased infant head circumference, growth restriction and decreased 95 birthweight (El Marroun et al., 2009; Fergusson, Horwood, & Northstone, 2002; Metz et al., 2017). 96 However, other studies failed to find negative effects of maternal cannabis use on neonatal 97 outcomes (Conner, Carter, Tuuli, Macones, & Cahill, 2015; Mark et al., 2016; Shiono et al. 1995; van 98 Gelder et al., 2010). Although some studies suggested initial delays in physical development, all 99 milestones are typically reached on time (Grant et al., 2017). Cognitive impairment has most 100 consistently been linked to fetal cannabis exposure (e.g., Fried & Watkinson, 2001; Fried, 101 
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Watkinson & Gray, 2003; Huizink & Mulder, 2006; Willford, Chandler, Goldschmidt & Day, 2010). 102 For example, prenatal cannabis exposure has been associated with certain deficits in visual and 103 cognitive function in children (Fried & Watkinson, 2000; Fried, Watkinson & Gray, 2003) and 104 decreased sustained attention in adolescents (Fried & Watkinson, 2001). A review of 36 clinical 105 studies found an association between fetal cannabis exposure and conduct disorder, although 106 causality could not be established (Ruisch, Dietrich, Glennon, Buitelaar, & Hoekstra, 2017).  107 Psychopathological conditions in younger adults, specifically anxiety and depression, are associated 108 with more frequent cannabis use (Hayatbakhsh, Najman, Jamrozik, Mamun, Alati & Bor, 2007) and 109 co-use use (Ramo, Liu & Prochaska, 2012). 110 Studies have demonstrated that the endogenous cannabinoid system is a key regulator of 111 immune function, with endogenous cannabinoid agonists, as well as exogenous ligands such as THC, 112 having immunosuppressant effects (reviewed in Olah, Szekanecz & Biro, 2017). Surprisingly, 113 however, little information is available regarding the impact of prenatal cannabis use or co-use on 114 immune function. Possible epigenetic mechanisms by which maternal cannabis use might impact 115 transgenerational immune function have been proposed (Dong et al., 2019; Zumbrun, Sido, 116 Nagarkatti & Natarkatti, 2015), but only a single experiment related to maternal cannabis use 117 appears to have been published. In that study, a mouse model was used to demonstrate that 118 prenatal cannabis exposure resulted in T-cell dysfunction in fetal and postnatal animals (Lombard, 119 Hegde, Nagarkatti & Nagarkatti, 2011).  120 To our knowledge, limited clinical data exist on the consequences of co-use of tobacco and 121 cannabis on maternal or fetal outcomes such as immune function. One recent study reported pre- 122 and postnatal dual exposure to tobacco and cannabis, when compared to tobacco- and cannabis-123 only groups, increased levels of secretory Immunoglobulin A, an essential antibody for mucosal 124 immunity in early childhood (Molnar et al., 2018). Given that tobacco and cannabis are two of the 125 most widely used substances during pregnancy, and that concurrent cannabis use might confer 126 
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additional or synergistic immunity and health risks in pregnant women who use tobacco, this 127 midpoint analysis from an ongoing project sought to describe the effects of first trimester co-use of 128 tobacco and cannabis on serum immune markers (IL-2, IL-6, IL-10, CRP, TNF-α and matrix 129 metalloproteinase [MMP]-8), as well as depression symptoms and perceived stress, compared to 130 tobacco use alone.  131 
2.1. Material and Methods 132 This report represents a preliminary midpoint analysis of a larger study to determine the 133 impact of prenatal tobacco use, including electronic nicotine delivery systems (ENDS), on immune 134 response and birth outcomes. Therefore, subject groups consisted of tobacco only users compared 135 to tobacco users who also tested positive for recent cannabis use; a cannabis use only group was 136 not included. An institutional review board (IRB) approved, multisite study using quota sampling 137 was used to meet study aims. Participants were recruited from academic and private prenatal clinics 138 in Kentucky via two methods: 1) women were approached at their obstetric screening 139 appointments; and 2) women proactively responded to posted study flyers. A study nurse 140 determined eligibility based on maternal age (18-44 years); first trimester gestation (less than 14 141 weeks), current tobacco use (within 30 days) and ability to read or write in English. Tobacco use was 142 limited to those who smoked conventional cigarettes and/or any form of ENDS. 143 A research nurse explained the study to eligible participants and obtained informed consent. 144 At enrollment, participants completed a survey (available via hard copy or iPad) that included 145 demographic, tobacco and psychosocial measures. The survey was written at the 6th grade level and 146 took approximately 20 minutes to complete. Survey responses were stored on REDCap, a secure 147 web-based data management system. Following survey completion, study personnel collected urine 148 and serum samples using previously reported methods (Ashford et al., 2017). These biomarkers 149 were used to determine study groupings (tobacco-only and tobacco plus cannabis). Participants 150 were given a $25 gift card to a local department store at completion of the study visit.  151 
 7 
 
2.1.1. Participants 152  Demographic information collected via survey included date of birth, race/ethnicity, partner 153 status, education and income. Age was calculated using the participant’s date of birth. Race and 154 ethnicity were assessed separately. First, respondents were asked to indicate whether they were 155 ‘Hispanic or Latino’ or ‘Not Hispanic or Latino’, and were then asked, ‘Which of the following best 156 describes your race?’ with response options including ‘American Indian/Alaskan Native,’ ‘Asian,’ 157 ‘Native Hawaiian or Other Pacific Islander,’ ‘Black or African American,’ ‘White’ and ‘More than 1 158 race.’ Responses from these two questions were combined and a dichotomous variable (‘White, non-159 Hispanic’ or ‘Non-white or Hispanic’) was used in subsequent analyses. Women were asked to select 160 their partner status from response options including ‘Single,’ ‘Married or living with a partner,’ 161 ‘Divorced or separated,’ ‘Widowed’ or ‘Other.’ Those who indicated ‘Married or living with a partner’ 162 were classified as partnered, while all other responses were coded as non-partnered. Employment 163 status was coded as employed (‘part-time’ or ‘full-time’) or unemployed (‘unemployed,’ ‘student’ or 164 ‘homemaker’). For education, women were asked ‘What is the highest grade or year of school you 165 have completed?’ with response options including ‘Less than high school graduate,’ ‘High school 166 graduate or GED,’ ‘Some college or vocational/trade school’ and ‘College graduate or beyond.’ For 167 analysis, the latter two categories were collapsed to represent beyond high school education. During 168 the first clinic visit (at enrollment), the research nurse recorded height and weight for each 169 participant, which was used to calculate body mass index. 170  Use of conventional and electronic cigarettes was assessed separately. For each product, the 171 research nurse asked ‘Have you used e-cigarettes/smoked cigarettes within the last 30 days?’ 172 Women who responded ‘yes’ were coded as current users of the respective product. Those who 173 responded ‘yes’ to electronic cigarettes were coded as dual or ENDS only users, while those who 174 responded ‘no’ were coded as conventional cigarette only users. 175 
 176 
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2.1.2. Biological Markers 177 Urine and serum samples were collected in the first trimester (8-14 weeks gestation). Urine 178 samples were assayed for the presence of nicotine and cannabis metabolites. Cotinine, a metabolite 179 of nicotine, has a half-life of approximately 9 hours in pregnant women (Bernert et al., 1997; 180 NicAlert, 2007) and was used to confirm tobacco status using a validated commercial assay 181 (NicAlert®). Cotinine levels greater than or equal to 100 ng/mL validated current tobacco use 182 (Ashford et al., 2010; Bernert, Harmon, Sosnoff, & McGuffey, 2005). 11-nor-9-carboxy-∆9-183 tetrahydrocannabinol (THC-COOH), a major metabolite of THC, was measured using a validated 184 analytical method for measurement of THC-COOH in urine using solid phase extraction and high 185 performance liquid chromatography coupled with negative mode electrospray ionization tandem 186 mass spectrometry. Similar methods have been used previously to assess cannabis use in pregnant 187 women (El Marroun et al., 2010; Westin, Huestis, Aarstad, & Spigset, 2008). Maternal serum 188 cytokines IL-1β, IL-2, IL-6, IL-8, IL-10, TNFα, CRP and MMP8 were determined from plasma samples 189 using methods previously reported (Ashford et al., 2017). The iCup Drug Screen (BioScan Screening 190 Systems, Inc., Smyrna, TN) was used to validate illicit drug use (McCarberg, 2011. The iCup employs 191 enzyme-linked immune assays (ELIZA) to detect the presence or absence of the following 192 drugs/drug classes: buprenorphine, morphine/opiates, methadone, oxycodone, benzodiazepines, 193 amphetamines, methamphetamine, cocaine, and THC. An indicator variable for other illicit drug use 194 was created to represent a positive test for any illicit substance use other than cannabis. Only one 195 participant tested positive for alcohol and this participant also tested positive for illicit drug use 196 other than cannabis. 197 
2.1.3. Psychological Measures 198 Maternal depressive symptoms and perceived stress were measured using tools validated 199 both during and after pregnancy. The 10-item Edinburgh Postnatal Depression Scale was used to 200 measure prenatal depressive symptoms (Gibson, McKenzie-McHarg, Shakespeare, Price, & Gray, 201 
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2009) and maternal stress was measured using the shortened, 4-item Perceived Stress Scale (PSS) 202 (Glynn, Schetter, Hobel, & Sandman, 2008; Karam et al., 2012). Both tools have demonstrated 203 consistent reliability throughout pregnancy (EDPS: Cronbach’s α = 0.82, 0.83, and 0.84, 204 respectively)(Bergink et al., 2011); 4-item PSS with a Cronbach’s α =0.79) (Karam et al., 2012). 205 
2.1.4. Statistical Analysis  206  Descriptive statistics summarized study variables. The two-sample t-test or chi-square test 207 of association, as appropriate, examined associations among sociodemographic variables and 208 subject group (i.e., co-use of tobacco and cannabis or tobacco use only). Multiple linear regression 209 models were used to determine differences in stress and depression by group, controlling for age, 210 race/ethnicity, partner status, education, income, tobacco use group (conventional cigarette only 211 versus dual or ENDS only user) and other illicit drug use. For the cytokine analysis, the Mann-212 Whitney U test compared users of both tobacco and cannabis to tobacco only users. Cytokine values 213 were log-transformed as an adjustment for lack of normality in the raw values and multiple linear 214 regression models tested for differences by subject group, adjusting for age, race/ethnicity, body 215 mass index, tobacco use group and other illicit drug use. All analysis was conducted using SAS, 216 version 9.4, with an alpha level of .05 throughout.  217 
3.1. Results 218 
3.1.1 Sociodemographic Characteristics   219 Urine drug tests were performed on 138 tobacco using pregnant women. Overall, 220 participants were primarily white (82%) and single/not partnered (53%). The average age was 221 29.1 years; 53% had a high school education or less and approximately half were unemployed. 222 Approximately one-quarter (24%) of women self-reported using ENDS, either alone or in 223 combination with cigarettes. Over one-quarter (28%) of women had a positive urine drug screen 224 for THC-COOH with a median level of 236 ng/ml (IQR=44-401). Pregnant women who reported co-225 use of tobacco and cannabis were younger than tobacco only users (27.3 [SD=5.0] vs 29.8 [SD=5.3] 226 
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years old; t(df=136) = 2.5, p=.02; Table 1). A higher proportion of co-users defined their race/ethnicity 227 to be other than White (41% vs 10%; χ2(df=1) = 16.5, p<.01) compared to tobacco only users. In 228 addition, compared to tobacco only users, a greater percentage of co-users listed their job status as 229 unemployed (68.7% vs 43.3%; χ2(df=1) = 6.2, p=.01).  230 Thirty percent of the participants (n=42) were positive for recent use of an illicit substance 231 other than cannabis in the first trimester. The most common substances were methamphetamine (n 232 = 36), prescription opioids (n = 34) and cocaine (n =7). There was no difference in the rate of urine 233 drug screens positive for any illicit drug between the groups (p=.86).  234 
3.1.2. Cytokine Levels  235  Cytokine data were available for 122 women in the first trimester. In the bivariate analysis, 236 there was a significant difference in TNF-α (m = 2.0 pg/mL [IQR=1.7-2.4] vs. m = 2.4 pg/mL 237 [IQR=2.0-2.8]; χ2(df=1) = 8.0, p = .01) and CRP (m = 5.3 mg/L [IQR=1.3-12.9] vs. m = 8.2 mg/L 238 [IQR=3.0-17.1]; χ2(df=1) = 4.6, p = .03; Table 2) levels between the two groups, with tobacco and 239 cannabis co-users having significantly lower levels compared to tobacco only users for both 240 inflammatory markers, respectively. In the adjusted linear regression models, there was no 241 difference in CRP between groups, while TNF-α levels remained lower among co-users (b =-0.15 242 [SE=0.07], p=.03), adjusting for age, body mass index, race/ethnicity, tobacco use group and other 243 illicit substance use. Because the cytokine values were log-transformed prior to modeling, the 244 geometric mean was interpreted, which indicated that co-users had approximately 14% lower TNF- 245 
α levels compared to tobacco only users (exp[beta] = 0.86). There were no differences by use group 246 for any of the other interleukins or MMP-8 in the unadjusted or adjusted models.  247 
3.1.3. Psychological Measures 248 On average, all participants had low stress levels (M=5.9, SD=3.3; potential range 0-16) and 249 depression scores (M=7.8, SD=5.8; potential range 0-30). There was no significant difference in 250 
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perceived stress or depressive symptoms as a function of use group in the unadjusted or adjusted 251 analysis. 252 
4.1. Discussion 253 There are well characterized adverse maternal, prenatal and child health effects of tobacco 254 cigarette use during pregnancy. Of concern is the recent escalation in daily cannabis use that has 255 been observed among female cigarette smokers (Goodwin et al., 2018) because concurrent 256 cannabis use might confer additional or synergistic maternal and/or fetal immunity and health 257 risks above those of tobacco. The present midpoint analysis from an ongoing project therefore 258 sought to describe the effects of first trimester co-use of tobacco and cannabis on serum immune 259 markers, as well as depression symptoms and perceived stress, compared to prenatal tobacco use 260 alone. Preliminary results from this analysis suggest that pregnant women co-using tobacco and 261 cannabis during the first trimester have decreased pro-inflammatory immune responsivity as 262 reflected by reduced TNF-α levels.  There were no differences in the other seven markers. 263 Little empirical information is available regarding the consequences of co-use of tobacco 264 and cannabis during pregnancy. Analyses of secondary data from a larger study on illicit and 265 prescription drug use during pregnancy indicated that relative to the use of only tobacco or 266 cannabis, co-use was significantly and positively correlated with smaller infant head circumference 267 and birth defects (Coleman-Cowger, Oga, Peters & Mark, 2018). Similarly, another study found that 268 smaller head size, an increased risk of preterm birth and decreased birth weight in the neonates 269 was associated with prenatal co-use of tobacco and cannabis compared to use of cannabis alone 270 (Chabarria et al., 2016). With respect to childhood effects of co-use of tobacco and cannabis, 271 offspring born to women who reported “decreasing co-use” (i.e., primarily during prenatal and 272 preschool periods) were more likely to be co-users themselves, and children of chronic co-users 273 were more likely to have a substance use disorder, relative to those whose mothers reported no co-274 use or only postnatal co-use (De Genna, Goldschmidt, Richardson, Cornelius & Day, 2018). In 275 
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addition, a recent study found that pre- and postnatal dual exposure increased secretory 276 Immunoglobulin-A in early childhood relative to tobacco and cannabis-only exposure (Molnar et al., 277 2018). The present preliminary results extend this limited literature by providing initial evidence 278 that co-use of cannabis and tobacco increases the likelihood of maternal immune system 279 dysregulation relative to the use of tobacco alone. 280 Lower socio-economic status, unemployment, and belonging to a racial minority group are 281 common in women who use cannabis during pregnancy (Chabarria et al., 2016; Conner et al., 2015; 282 Metz et al., 2017; van Gelder et al., 2010). Among tobacco users, co-users of cannabis are more 283 likely to be younger and non-Hispanic Black or Hispanic relative to tobacco only users (Coleman-284 Cowger et al., 2017), consistent with the current findings. Although demographic characteristics 285 differ between groups, a comprehensive and inclusive approach for identifying and providing 286 cessation interventions should be provided to all co-users of tobacco and cannabis. Future research 287 may also explore the efficacy of interventions tailored to meet the unique needs of distinct 288 demographic groups.  289 Pregnancy is characterized by a physiologic systemic inflammatory response that fluctuates 290 over the course of the pregnancy (Romero, Gotsch, Pineles & Kusanovic, 2007). Tobacco use during 291 pregnancy is associated with a maternal shift in anti-inflammatory and pro-inflammatory cytokines 292 that can negatively affect fetal outcomes (Ashford et al., 2013; Simhan et al., 2005). To our 293 knowledge, no clinical research has been conducted on the effects of prenatal cannabis use, or co-294 use of tobacco and cannabis, on maternal, fetal or child cytokine composition. The present study is 295 the first to report that women who co-use tobacco and cannabis exhibit a depressed pro-296 inflammatory response, as evidenced by significantly lower TNF-α levels, relative to tobacco-only 297 users. TNF-α is a byproduct of macrophages that are responsible for apoptosis, and during 298 pregnancy, are lowest in the first trimester compared to the third trimester (Ashford et al., 2017).  299 
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Current research reporting the effects of tobacco or co-use of tobacco and cannabis on 300 cytokine levels is mixed (Klein, T., Lane, B., Newton, C. & Friedman, H., 2000), yet largely examines 301 the effects of medical marijuana in patients with chronic inflammatory conditions (e.g. rheumatoid 302 arthritis) (Nagarkatti, P., Pandey, R., Rieder, S., Hegde, V., & Nagarkatti, M., 2009). In other in-vivo 303 and murine work independently examining cannabis and tobacco, potential effects contributing to 304 TNF-α suppression included the use of unheated THC (Verhoeckx, K. et al., 2006) and higher doses 305 of nicotine (Li-Sha, G. et al., 2015). Further reductions in first trimester TNF-α by the co-use of 306 tobacco and cannabis could compromise the immune system balance between maintaining 307 maternal health and tolerating the semiallogeneic fetus, thereby negatively affecting birth outcomes 308 (Dong et al., 2019). These group differences in TNF-α could be due to the use of cannabis or 309 additive/synergistic effects of tobacco and cannabis in the co-use group, and/or the differing 310 demographic characteristics of the two groups. Further research is needed to uncover the factors 311 driving these group differences. 312 Maternal psychosocial factors such as stress, depression, and anxiety have been linked with 313 tobacco use (Goodwin, Keyes, Simuro, 2007; Hauge, Torgersone, Vollrath, 2012; Zhu & Valbo, 2002) 314 and cannabis use during pregnancy (Conner et al., 2015; Hayatbakhsh et al., 2007; Mark et al., 2016; 315 Oh, Salas-Wright, Vaughn, & DiNitto, 2017; Ramo, Liu, Prochaska, 2012), although we are not aware 316 of any studies that have specifically examined the presence of psychiatric disorders in pregnant co-317 users. The present midpoint analysis suggests that maternal stress and depressive symptoms do 318 not differ between these groups. Prior studies have compared tobacco-using women and non-319 tobacco-using women and found an association between tobacco use and psychological stress and 320 depression (Husky, Mazure, Paliwal, & McKee, 2008). The present study exclusively recruited 321 tobacco-users, so it is plausible that differences in perceived stress or depressive symptoms were 322 not detected due to the homogeneity of having a sample consisting of all prenatal tobacco users. 323 
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Another possibility is that stress and depressive symptom scores were relatively low in both groups 324 making group differences difficult to detect (i.e., a floor effect).  325 Some study limitations warrant mentioning. Weaknesses of this midpoint analysis include 326 the small sample size, the lack of additional comparison groups (i.e., women without exposure to 327 tobacco, and those with cannabis only), and the inability to control for exposures to various 328 medications that might impact study outcomes, such as antibiotics or anxiolytics. Further, there 329 was only one participant with a multiple pregnancy, therefore we were unable to address the 330 potential impact this may have on both psychosocial and immune function. Another limitation is 331 that self-reported cannabis data were not collected. Instead, the presence of urinary THC and level 332 of cotinine (> 100 ng/mL) were used for co-use group assignment. Given the varied detection 333 window for urinary THC, it is possible that one or more co-users were misclassified as a tobacco 334 only user, which might have impacted our ability to detect relationships between co-use and 335 maternal outcomes. In addition, the lack of quantitative self-reported use data precluded 336 determination of dose-response relationships. Although standards for the expected concentrations 337 of immune markers at different timepoints during pregnancy have not been established, one 338 possibility is that the varied collection times within the first trimester (weeks 8-13) might have 339 yielded variability in immune markers (Aghaeepour, N. et al., 2017), which also might have 340 impacted our ability to detect relationships between co-use and maternal outcomes. Despite these 341 limitations, the preliminary findings from this midpoint analysis provide the premise for future 342 studies to examine changes in cytokines over the course of pregnancy in women who use tobacco 343 and cannabis.  344 
5.1. Summary and Conclusion 345 This analysis appears to be the first to compare markers of immune and psychosocial 346 function in first trimester pregnant women who co-use tobacco and cannabis to those in tobacco-347 only users. These preliminary results suggest that pregnant women co-using tobacco and cannabis 348 
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are more likely to be non-White, younger and more economically disadvantaged compared to 349 tobacco-only users. These preliminary results also suggest that co-use in the first trimester is 350 associated with a depressed proinflammatory immune response, as reflected by one immune 351 marker, TNF-α.  Additional research to measure the range of maternal and fetal immune 352 responsiveness during gestation, as well as long-term follow-up of offspring of women who co-use 353 tobacco and cannabis, is warranted. These findings also support research that includes appropriate 354 comparison groups to disentangle the unique contribution of cannabis use relative to tobacco and 355 cannabis co-use on maternal immune function. 356 
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Table 1. Sociodemographic characteristics of the study sample  620  Variable   Total sample (N = 138) 
Mean (SD)  or n (%) 
Prenatal exposures  test statistic   p Tobacco 
and 
cannabis (n = 38) 
Mean (SD)  or n (%) 
Tobacco 
only  (n = 100) 
Mean (SD)  or n (%) Age  29.1 (5.4) 27.3 (5.0) 29.8 (5.3) t(df=136) = 2.5 .02 Body mass index (kg/m2)  29.4 (8.3) 28.1 (8.1) 29.8 (8.4)  .29 Race/ethnicity  Non-White or Hispanic  White  
 24 (18.1%) 109 (81.9%)  
 14 (41.2%) 20 (58.8%)  10 (10.1%) 89 (89.9%) χ2(df=1) = 16.5 <.01 Partnered   Yes   No  
 61 (47.3%) 68 (52.7%)  12 (37.5%) 20 (62.5%)  49 (50.5%) 48 (49.5%) χ2(df=1) = 1.6 .20 Education   Less than high school   High school graduate   Beyond high school  
 18 (13.7%) 52 (39.7%) 61 (46.6%) 
 5 (15.1%) 15 (45.5%) 13 (39.4%) 
 13 (13.2%) 37 (37.8%) 48 (49.0%) 
χ2(df=2) = 0.9 .63 
Employment status   Employed   Unemployed  
 65 (50.4%) 64 (49.6%)  10 (31.3%) 22 (68.7%)  55 (56.7%) 42 (43.3%) χ2(df=1) = 6.2 .01 Tobacco use group   Conventional cigarettes only   Dual or ENDS only  
 99 (76.2%) 31 (23.8%)  27(79.4%) 7 (20.6%)  72 (75.0%) 24 (25.0%) χ2(df=1) = 0.3 .60 Other illicit drug use   Yes   No  38 (27.5%) 100 (72.5%)  12 (31.6%) 26 (68.4%)  30 (30.0%) 70 (70.0%)  
χ2(df=1) < 0.1  .86 
Stressa  5.9 (3.3) 5.8 (3.4) 6.0 (3.2) t(df=128) = 0.4 .72 Depressionb  7.8 (5.8) 7.5 (6.0) 7.9 (5.8) t(df=136) = 0.1 .75 
Note: Numbers vary due to missing data. Abbreviation: ENDS, electronic nicotine delivery system621 a Stress measured by the 4-item Perceived Stress Scale; potential scores range from 0-16, with 622 higher scores reflecting more perceived stress 623 b Depressive symptoms measured using the 10-item Edinburgh Postnatal Depression Scale; 624 potential scores range from 0-30 625 
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Table 2. Unadjusted and adjusted associations among cytokines and cannabis use     Cytokine  
Prenatal exposures  
 Unadjusted 
pa 
  Adjusted 
pb 
Tobacco and Cannabis  (n = 34) 
 
Median (IQR) 
 Tobacco only   (n = 87) 
 
Median (IQR) 
IL 1β (pg/mL) 0.09 (0.05 – 0.13) 0.08 (0.06 – 0.11) .36 .43 IL 2 (pg/mL) 0.13 (0.07 – 0.26) 0.11 (0.07 – 0.22) .59 .28 IL 6 (pg/mL) 0.74 (0.49 – 1.04) 0.69 (0.50 – 1.12) .95 .18 IL 8 (pg/mL) 2.52 (2.06 – 3.38) 2.91 (2.28 – 4.02) .06 .11 IL 10 (pg/mL) 0.30 (0.21 – 0.42) 0.27 (0.22 – 0.46) .81 .58 TNF-α (pg/mL) 2.03 (1.69 – 2.36) 2.35 (1.98 – 2.75) <.01 .03 CRP (mg/L) 5.34 (1.26 – 12.94) 8.18 (3.03 – 17.05) .03 .26 MMP 8 (ng/mL) 27.70 (16.01 – 38.33) 36.33 (19.25 – 60.73) .10 .76 
a p-value from Mann-Whitney U test 
b p-value from multiple linear regression model adjusting for age, body mass index, race/ethnicity, tobacco use group and other illicit substance use. 
